Tackling CMV in Transplant Recipients: Past, Present, and Future
Abstract Cytomegalovirus (CMV), a beta-herpesvirus capable of maintaining lifelong latency, presents a substantial risk to transplant recipients, resulting in significant morbidity and mortality among both hematopoietic stem cell and solid organ transplantation recipients. Recent advances have shift...
Saved in:
| Main Authors: | Tal Schlaeffer-Yosef, Lior Nesher |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-04-01
|
| Series: | Infectious Diseases and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40121-025-01159-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dual Resistance to Maribavir and Ganciclovir in Transplant Recipients
by: Steven B. Kleiboeker
Published: (2025-03-01) -
A novel strategy for the management of cytomegalovirus retinitis in immunocompromised patients using new anti-cytomegalovirus drugs
by: Yuou Yao, et al.
Published: (2025-06-01) -
Real-world efficacy and safety of letermovir versus ganciclovir prophylaxis in adolescent patients undergoing allogenic hematopoietic stem cell transplantation: a single center observational study
by: Ziwei Xu, et al.
Published: (2025-06-01) -
LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM?
by: Fabian Herrera
Published: (2024-04-01) -
In Silico Analysis of Mechanisms of Maribavir-Induced Inhibition and Drug Resistance Mutations in pUL97 Kinase Structural Prediction with AlphaFold2
by: Jocelyne Piret, et al.
Published: (2025-07-01)